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ABSTRACT 
After liver metastases, Peritoneal Carcinomatosis (PC) is the second most frequent cause of death in patients with Co-
lorectal Cancer (CRC), although the precise incidence of Colorectal Cancer Peritoneal Carcinomatosis is not known, as 
the majority of the diagnostic studies cannot detect the disease in its initial stages, nowadays, the diagnosis of peritoneal 
carcinomatosis remains a challenge. The molecular biology of PC is only just beginning to be understood, future 
knowledge will permit not only identify novel strategies for PC prevention, but also contribute to therapeutic advances, 
through the development of molecular targeted therapies. The authors performed a literature revision about the Molecu-
lar Biology, Diagnosis and Management of Colorectal Cancer Peritoneal carcinomatosis. 
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1. Introduction 
Peritoneal carcinomatosis (PC) consisted in the implanta- 
tion of tumour cells throughout the peritoneal cavity [1] 
and, until recently, has been associated with a poor 
prognosis and considered a almost untreatable condition 
[1,2]. 
In Colorectal Cancer (CRC), the precise incidence of 
PC is not known, as the majority of the CRC follow-up 
studies cannot detect the disease in its initial stages [2]. It 
is estimated that, at the time of diagnosis, the peritoneal 
surface is already involved in 10% - 15% of cases [2], 
and that, after CRC curative surgical resection, PC oc- 
curs in up to 50% of patients [2,3]: 4% - 19% during fol- 
low-up time and in almost 44% of the patients who re- 
quire relaparotomy [4]. In 25% of patients, CRC recur- 
rence is confined to the peritoneal cavity [2,4]. 
After liver metastases, PC is the second most frequent 
cause of death in patients with CRC [1,4] and it is pre- 
sent in 40% - 80% of patients who die from CRC [4]. 
Natural history studies show that Colorectal cancer PC 
is considered a terminal disease, with an median sur- 
vival of 6 - 8 months [3,5], so treatment of this dissemi- 
nated condition represents one of the Oncology limits 
[2,5]. Occasionally, patients needed a surgical intervene- 
tion for intestinal occlusion, haemorrhage, or perforation 
caused by CP but most realized laparotomies for taking 
biopsies and then being referred to their oncologists for 
treatment with systemic chemotherapy [2]. Nowadays, 
with the introduction of locoregional therapies, promis- 
ing results are suggested by several centers, namely cy- 
toreductive surgery (CRS) combined with intraoperative 
intraperitoneal chemotherapy (PIC) without/with hyper-
thermia [1,3]. 
2. Molecular Biology of Colorectal Cancer 
Peritoneal Carcinomatosis 
Presently, our understanding of the molecular events 
involved in PC is ill-understood [6], future knowledge 
will permit not only identify novel strategies for PC pre- 
vention, but also contribute to therapeutic advances, 
through the development of molecular targeted therapies 
[7]. 
The development of PC involves a complex sequence 
of continuous and interdependent steps [8-10], known as 
the “peritoneal metastatic cascade” [6]; including cell *Corresponding author. 
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shedding and transport, adhesion to the mesothelial layer, 
invasion and proliferation into the submesothelial stroma, 
and potential access to the systemic circulation [9,10]. 
In the Peritoneal Tumour Dissemination step, the 
tumour cells are release from the primary tumour and 
gain access to the peritoneal cavity [6,7]. This can occur 
by several mechanisms namely, spontaneous exfoliation 
of tumour cells from the primary tumour, by iatrogenic 
or spontaneous perforation of the primary tumour or 
from transected lymphatics and blood vessels during tu- 
mour surgical resection [7]. After this, cancer cells are 
seeded in the peritoneal cavity and factors like gravity, 
peristaltic abdominal viscera movement and the flow of 
ascitic fluid resulting from the negative pressure exerted 
by diaphragm movements, contribute for the final desti- 
nation of tumour cells, that adheres to the mesotelium, in 
the Mesothelial Adhesion step, and then can penetrate 
the mesothelial layer, gaining access to the submesothe- 
lial connective tissue, in the Mesothelial Invasion step, 
and then invading the underlying connective tissue; this 
environment provides the necessary scaffold for tumour 
proliferation that result in the establishment of metastatic 
tumour deposit, in the Stromal Invasion and Prolifera- 
tion step. The final step involves the Induction of An- 
giogenesis to sustain tumour proliferation and enable 
further metastatic growth [6,7]. 
Some of the molecules involved in the “peritoneal 
metastatic cascade” have already been identified. In the 
Peritoneal Tumour Dissemination step, the detach- 
ment of cells from the primary tumour, can be mediated 
by the down-regulation of intercellular adhesion mole- 
cules on the tumor cell surface, E-cadherin, namely type 
I cadherins [7,8,11]. Next, free tumour cells invades the 
subperitoneal tissue, through matrix metalloproteinases 
(MMPs), such MMP-7, and directly attach to the sub- 
mesothelial barrier connective tissue [through interaction 
with integrins, selectins and CD44, a lymphocyte homing 
molecules], in the Mesothelial Adhesion step [7,8,11]. 
In Mesothelial Invasion step, the production of cyto- 
kines, like interleukins, Endothelial Growth Factor (EGF), 
Hepatocyte Growth Factor (HGF), Vascular Endothelial 
Growth Factor-C (VEGF-C); induces the contraction of 
mesothelial cells exposing the submesothelial basement 
membrane and tumor cells can adhere to the submesothe-
lial connective tissue through the interaction of integrins. 
The invasion of subperitoneal tissue requires the degra-
dation of the peritoneal blood barrier by motility factors 
and matrix proteinases, the MMPs may play a central 
role Stromal Invasion and Proliferation step like 
urokinase plasminogen activating system. The next step, 
Induction of angiogenesis in the subperitoneal space is 
mediated by the production of VEGF-A and VEGF-C 
[7]. 
Another mechanism is described to peritoneal cancer 
dissemination, the translymphatic process; according to 
this process the peritoneal free cancer cells gain access to 
the subperitoneal lymphatic spaces through lymphatic 
stomata and milky spots that are abundant in the greater 
omentum, appendices epiploicae of the colon, inferior 
surface of the diaphragm, falciform ligament, Douglas 
pouch and small bowel mesentery. On the other hand the 
peritoneum covering the liver and the serosal surface of 
small bowel and spleen are devoid of lymphatic stomata 
as well as milky spots and thus are involved in peritoneal 
dissemination of cancer cells only in the late stage of 
peritoneal carcinomatosis [7]. 
3. Diagnosis of Colorectal Cancer Peritoneal 
Carcinomatosis 
CRC is one of the most frequent cause of PC [12], but 
the diagnosis, of this condition, at initial stages is very 
difficult [2], as it can be limited to the ascitic fluid [13]. 
Future improvements in earlier diagnosis are essential to 
prevent unnecessary laparotomies and to select the pa- 
tients in whom complete cytoreduction is feasible [14]. 
Computed tomography (CT) is generally considered as 
the first-choice modality for detecting PC [14], with 
varying sensitivity results ranging widely from 17% to 
54% [13] so, limited capacity for demonstrating PC [14]. 
Most CT scan findings are nonspecific; on the one hand, 
both neoplastic and non-neoplastic pathologies can pre- 
sent as soft-tissue peritoneal masses, with or without as- 
cites [15]; on the other hand, TC sensibility depends on 
factors such as size, site, tumour deposit morphology, 
presence of ascites and paucity of intraabdominal fat [13]. 
Peritoneal tumor deposits are often small, and may be 
few in number or may extend along the parietal or vis- 
ceral peritoneum and cause omental caking [13,15]. 
Some studies have demonstrated improved lesion de- 
tection with magnetic resonance imaging (MRI) [16,17], 
but not all [18]. 
Early detection of recurrence and high sensitivity and 
specificity has been reported with 18F-FDG PET [19]. 
Yoshiko Bamba et al. [14] document levels of detectabil- 
ity of PC from CRC using PET/CT of 82.6%. 
Evaluation of PC with 18F-FDG PET studies can iden- 
tify two distinct patterns of glucose metabolism that ap- 
pear to predict either nodular or diffuse peritoneal pa- 
thology and should alert the clinician to the possibility of 
PC [13]. It is most suitable in patients with high tumor 
markers and negative or uncertain conventional imaging 
data and in selecting patients for complete cytoreduction 
[20]. 
4. Management of CRC Peritoneal 
Carcinomatosis 
The management of PC from CRC is evolving. In recent 
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years, with the introduction of regional therapy and new 
chemotherapeutic and biologic agents, the outcomes for 
these patients has improved [21] but careful patient se- 
lection is needed, because of its significant but accept- 
able morbidity/mortality and cost [10,22]. Results of 
large multicentre studies have identified several prognos-
tic factors that can be used to improve selection of CRC 
with carcinomatosis who will benefit from cytoreductive 
surgery (CRS) with hyperthermic intraperitoneal chemo- 
therapy (HIPEC). The extent of colorectal carcinomatosis 
has been shown to be the most important prognostic fac- 
tor determining survival [21]. 
Actually, the efficacy of CRS and HIPEC as a treat- 
ment option for PC from CRC is an established part of 
the oncologic literature [21,23] and CRS in combination 
with HIPEC for peritoneal surface disease has been 
demonstrated to produce survival outcomes similar to 
liver resection for hepatic metastases [24]. 
The aim of surgery is to remove all macroscopically 
visible tumor implants from the visceral and parietal 
peritoneum; thus, cytoreductive surgery consisted of a 
variety of peritonectomy procedures, whose extent de- 
pends of peritoneum tumor infiltration, but often mul- 
tivisceral resections are necessary to achieve complete 
macrosopical cytoreduction [25,26]. 
After complete cytoreduction, HIPEC is realized and 
the abdominal and pelvic spaces are flooded by a warm 
chemotherapy solution, the heated circulation was main- 
tained for one additional hour. During the time of perfu- 
sion, the operating table is moved in all possible direc- 
tions to guarantee optimal distribution of the heated 
agent within the abdomen [23]. These treatments may be 
continued with early postoperative intraperitoneal che- 
motherapy (EPIC), using cell cycle-specific drugs that 
should contact all visceral and parietal surfaces because 
their use precedes the development of abdominal adhe- 
sions [23]. 
Until more data become available, the management 
strategy supported by the literature is CRS plus HIPEC. 
Based on current evidence, modern chemotherapies for 
patients with CRC carcinomatosis achieves a median sur- 
vival of 24 months compared to the 63 months achived 
for CRS plus HIPEC, with a 5-year survival of 51% [21, 
23]. 
5. Conclusions 
Peritoneal Carcinomatosis from Colorectal cancer is pro- 
bably an underdiagnosed condition, as earlier diagnosis 
of this condition is very difficult. 
Recent advances in the molecular biology knowledge 
will not only enable only identify novel strategies for PC 
prevention and earlier detection, but also improve treat- 
ment through the development of molecular targeted 
therapies. 
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